Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Xeris Biopharma Holdings' Free Cash Flow rose 321.94% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 133.53%. This contributed to the annual value of -$37.0 million for FY2024, which is 21.36% up from last year.
  • Xeris Biopharma Holdings' Free Cash Flow amounted to $18.4 million in Q3 2025, which was up 10,027.47% from $182,000 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Free Cash Flow registered a high of $18.4 million during Q3 2025, and its lowest value of -$48.4 million during Q1 2022.
  • Moreover, its 3-year median value for Free Cash Flow was -$10.0 million (2025), whereas its average is -$6.9 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Free Cash Flow plummeted by 162.10% in 2021, and later spiked by 321.94% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Free Cash Flow (Quarterly) stood at -$29.1 million in 2021, then soared by 44.56% to -$16.1 million in 2022, then skyrocketed by 146.35% to $7.5 million in 2023, then tumbled by 73.56% to $2.0 million in 2024, then skyrocketed by 321.94% to $18.4 million in 2025.
  • Its Free Cash Flow stands at $18.4 million for Q3 2025, versus $182,000 for Q2 2025 and -$10.0 million for Q1 2025.